EUVIMEDEUVIMED entdecken
Crossref

Trump orders ibogaine and other psychedelics on fast track at FDA

Alison Knopf

Alcoholism & Drug Abuse Weekly · 27.04.2026 · 38 (17) · 1-3

DOI: 10.1002/adaw.34891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alcoholism & Drug Abuse Weekly, online erschienen am 24.04.2026. Verfasst von Alison Knopf.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On April 17, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to “establish a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds.” While citing the need for solutions to treatment‐resistant mental illness, Trump also required the U.S. Department of Health and Human Services (HHS) to allocate $50 million through the Advanced Research Projects for Health (ARPA‐H) program to match investments made by state governments to advance research into psychedelic programs for populations with serious mental illness.

Zitieren

APA

Knopf, A. (2026). Trump orders ibogaine and other psychedelics on fast track at FDA. Alcoholism & Drug Abuse Weekly, 38(17), 1-3. https://doi.org/10.1002/adaw.34891

Vancouver

Knopf A. Trump orders ibogaine and other psychedelics on fast track at FDA. Alcoholism & Drug Abuse Weekly. 2026;38(17):1-3. doi:10.1002/adaw.34891

BibTeX
@article{Knopf2026,
  author = {Knopf, Alison},
  title = {Trump orders ibogaine and other psychedelics on fast track at FDA},
  journal = {Alcoholism & Drug Abuse Weekly},
  year = {2026},
  volume = {38},
  number = {17},
  pages = {1--3},
  doi = {10.1002/adaw.34891}
}
Kostenlos starten →